oral semaglutide weight loss fda Sets Action Date for Wegovy for The FDA has just approved

Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5 mg, 10 mg, and 15 mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo

Although both drugs were extensively studied before approval, semaglutide has only been on the market since 2017 and tirzepatide since 2022

This question concerns many patients considering this dual GIP/GLP-1 receptor agonist for type 2 diabetes or weight management

Many patients begin noticing changes within the first several weeks of treatment, while meaningful progress often continues over the following months